Why Barclays Thinks Ionis Is Headed for a 45% Surge From $73 to $106

Ionis Pharmaceuticals has risen 137.52% over the past 12 months; the stock is down 6.12% year-to-date and trading about 7.20% below its one-month high, near $72.70. This piece is a price-performance snapshot rather than new fundamental or corporate news, highlighting strong 1-year appreciation with a modest short-term pullback.

Analysis

Ionis Pharmaceuticals has risen 137.52% over the past 12 months; the stock is down 6.12% year-to-date and trading about 7.20% below its one-month high, near $72.70. This piece is a price-performance snapshot rather than new fundamental or corporate news, highlighting strong 1-year appreciation with a modest short-term pullback.